$363 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARIA | ARIAD PHARMACEUTICALS INC | $159,853,000 | -9.1% | 12,850,000 | 0.0% | 44.03% | +8.7% | |
| BIIB | BIOGEN INC | $87,909,000 | -9.4% | 310,000 | 0.0% | 24.21% | +8.3% | |
| MDCO | MEDICINES CO | $59,462,000 | -10.1% | 1,752,000 | 0.0% | 16.38% | +7.6% | |
| INVA | Buy | INNOVIVA INC | $31,832,000 | +189.6% | 2,975,000 | +197.5% | 8.77% | +246.4% |
| NVLNF | New | NOVELION THERAPEUTICS INC | $8,630,000 | – | 1,025,000 | +100.0% | 2.38% | – |
| ITCI | Sell | INTRA CELLULAR THERAPIES INC | $5,432,000 | -47.2% | 360,000 | -46.7% | 1.50% | -36.9% |
| ADXS | Sell | ADVAXIS INC | $3,579,000 | -44.2% | 500,000 | -16.7% | 0.99% | -33.2% |
| VVUS | VIVUS INC | $2,960,000 | +0.9% | 2,573,943 | 0.0% | 0.82% | +20.6% | |
| APRI | New | APRICUS BIOSCIENCES INC | $1,882,000 | – | 1,447,906 | +100.0% | 0.52% | – |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $917,000 | -48.5% | 1,700,000 | -15.0% | 0.25% | -38.3% |
| ABBV | Sell | ABBVIE INC. | $626,000 | -69.0% | 10,000 | -68.8% | 0.17% | -63.0% |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -50,000 | -100.0% | -0.97% | – |
| APRI | Exit | APRICUS BIOSCIENCES INC | $0 | – | -14,479,052 | -100.0% | -1.13% | – |
| AEGR | Exit | AEGERION PHARMACEUTICALS INC | $0 | – | -2,649,000 | -100.0% | -1.81% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -430,000 | -100.0% | -3.39% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -4,300,000 | -100.0% | -6.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.